A silver lining in the pipeline
- Improving Productivity With Model-Based Drug Development: An Enterprise Perspective. Grasela, T. H.; Slusser, R. // Clinical Pharmacology & Therapeutics;Aug2010, Vol. 88 Issue 2, p263
The article focuses on the need of model-based drug development (MBDD) process for improving the productivity of the pharmaceutical industry. As reported, pharmaceutical industry is facing a crisis in research and development (R&D) and though several companies have moved toward a more proactive...
- Improving R&D productivity. Smietana, Katarzyna; Ekstrom, Leeland; Jeffery, Barbara; Møller, Martin // Nature Reviews Drug Discovery;Jul2015, Vol. 14 Issue 7, p455
The article looks at the aspects of productivity in the research and development (R&D) sector of the pharmaceutical industry. Topics discussed include productivity improvement brought by R&D cost and product revenues, R&D investments in anti-infectives, and strategies for companies to improve...
- The impact of mergers on pharmaceutical R&D. LaMattina, John L. // Nature Reviews Drug Discovery;Aug2011, Vol. 10 Issue 8, p559
Mergers and acquisitions in the pharmaceutical industry have substantially reduced the number of major companies over the past 15 years. The short-term business rationale for this extensive consolidation might have been reasonable, but at what cost to research and development productivity?
- Trend Watch. // Drug Discovery & Development;Jun2005, Vol. 8 Issue 6, p18
The article presents a graphical representation of the estimated pharmaceutical research and development expenditure in China for the period 2002-2006. The trend shows that the research and development expenditure in the field of drug development is increasing gradually since 2002.
- Investors supportive despite pharma's shrinking returns. Winter, Peter // BioWorld Insight;12/9/2013, Vol. 21 Issue 50, p3
The article discusses a report on pharmaceutical industry which revealed increase in cost of assets to launch therapeutic drugs from 2010 to 2013. It also discusses initiatives of several pharmaceutical companies to expand its operations such as creating greater efficiencies, reforming research...
- What Constitutes an Optimal Portfolio of Pharmaceutical Compounds? Dimitri, N. // Clinical Pharmacology & Therapeutics;Feb2011, Vol. 89 Issue 2, p304
The business perspectives of a pharmaceutical firm (PF) are crucially affected by its portfolio of compounds under development. For this reason, companies strive to optimize the contents of their drug development pipelines. Can an "optimal portfolio" be uniquely defined? In this article, I...
- R&D costs are on the rise. // Medical Marketing & Media;Jun2003, Vol. 38 Issue 6, p14
Reports on the increase in the cost of developing new drugs, according to a study from the Tufts Center for the Study of Drug Development. Increase in fully capitalized development costs; Results of a November 2001 analysis of development costs.
- Toxicologic Pathology in a Multicultural Worldï¿½India. Schultze, A. Eric; Reddy, Vijayapal R.; Donnelly, Kevin B.; Berridge, Brian R. // Toxicologic Pathology;Oct2011, Vol. 39 Issue 6, p1003
The global practice of drug development is expanding into many different continents and countries. India, in particular, is rapidly emerging as an economic force in this arena by offering ever-expanding opportunities for pharmaceutical market expansion as well as productive drug development...
- Opaque Times. W�nsche, Guido; Kortmann, Sebastian // Journal of Business Chemistry;Sep2011, Vol. 8 Issue 3, p99
An introduction to the journal is presented in which the editor discusses various reports within the issue on topics including research and development spin-outs on drug discovery, the development of strategies and eco-innovation of pharmaceutical companies.